March 25, 2020 / 1:41 PM / 12 days ago

REFILE-UPDATE 2-China suspends Bristol-Myers' cancer drug sales over findings at U.S. plant

(Corrects to "plant" from "pant" in paragraph 1)

March 25 (Reuters) - Sales of Bristol-Myers Squibb Co's cancer drug Abraxane have been suspended in China based on findings at a third-party manufacturing plant in the United States.

The suspension by the China National Medical Products Administration was announced by partner Beigene Ltd and confirmed by Bristol-Myers on Wednesday.

Beigene and Bristol-Myers were working to restore supply as soon as possible, said China-based Beigene, which signed an agreement with Bristol-Myers' Celgene unit in 2017 to market and distribute Abraxane.

"This decision only applies to the China market and does not impact our ability to supply Abraxane outside of China," Bristol-Myers said in an emailed statement.

The drug brought in sales of $1.2 billion for Bristol-Myers in 2019.

Along with remediation efforts at the U.S. site, Bristol-Myers has applied for approval to source its supply of Abraxane for the China market from an alternative manufacturing facility, Beigene said. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli and Vinay Dwivedi)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below